Aurdan Capital Management LLC Makes New Investment in CVS Health Co. (NYSE:CVS)

Aurdan Capital Management LLC purchased a new stake in CVS Health Co. (NYSE:CVS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,640 shares of the pharmacy operator's stock, valued at approximately $478,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Stonebridge Financial Group LLC purchased a new stake in shares of CVS Health in the 4th quarter valued at about $28,000. Hopwood Financial Services Inc. bought a new position in shares of CVS Health during the 4th quarter valued at about $29,000. McIlrath & Eck LLC increased its position in shares of CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares during the last quarter. Financial Perspectives Inc increased its position in shares of CVS Health by 137.5% during the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after purchasing an additional 466 shares during the last quarter. Finally, MidAtlantic Capital Management Inc. increased its position in shares of CVS Health by 112.1% during the 4th quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator's stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

Insiders Place Their Bets

In other CVS Health news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This represents a 47.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.22% of the company's stock.

CVS Health Trading Up 1.7%

CVS traded up $1.06 during midday trading on Wednesday, reaching $62.40. 9,150,745 shares of the company's stock traded hands, compared to its average volume of 11,292,974. The firm has a fifty day moving average of $65.86 and a two-hundred day moving average of $59.46. The stock has a market capitalization of $78.94 billion, a price-to-earnings ratio of 17.05, a P/E/G ratio of 0.98 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. CVS Health's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.31 EPS. On average, equities analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.26%. CVS Health's dividend payout ratio (DPR) is 63.48%.

Wall Street Analyst Weigh In

CVS has been the topic of several recent research reports. Leerink Partnrs upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 12th. Wolfe Research increased their price objective on CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Finally, Truist Financial increased their price objective on CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research report on Monday, May 12th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $74.94.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.